Price
805.45
-0.77%52W Range
Market Cap
₹6,482.49 Cr
Traded: ₹10.20 Cr (0.16%) 0.0x
Free Float: ₹1,310.11 Cr (0.78% of FF traded)
Volume · 60D trend
1.27 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Return | -- | -- | +44.0% | +25.0% | -- | Decelerating |
| Profit | -- | +11.0% | +33.0% | -- | +12.0% | Stable |
| Sales | -- | +16.0% | +22.0% | -- | +28.0% | Accelerating |
| ROE | +23.0% | +20.0% | +19.0% | -- | -- | Decelerating |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 190 | 277 | 206 | 200 | 145 | 184 | 186 | 166 | 161 | 158 | 140 | 140 | 132 | 142 |
| Expenses | 142 | 179 | 134 | 127 | 93 | 117 | 120 | 101 | 98 | 103 | 99 | 108 | 88 | 87 |
| Operating Profit | 47 | 98 | 72 | 73 | 52 | 68 | 66 | 65 | 63 | 56 | 41 | 32 | 44 | 55 |
| OPM % | 25.0% | 35.0% | 35.0% | 36.0% | 36.0% | 37.0% | 36.0% | 39.0% | 39.0% | 35.0% | 30.0% | 23.0% | 34.0% | 39.0% |
| Other Income | 3 | 3 | 2 | 3 | 3 | 3 | 2 | 3 | 2 | 2 | 3 | 2 | 3 | 2 |
| Interest | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| Depreciation | 9 | 8 | 7 | 7 | 6 | 6 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 3 |
| Profit Before Tax | 41 | 92 | 67 | 68 | 47 | 64 | 63 | 62 | 60 | 53 | 40 | 30 | 43 | 53 |
| Tax % | 41.0% | 19.0% | 26.0% | 26.0% | 27.0% | 21.0% | 25.0% | 26.0% | 25.0% | 31.0% | 26.0% | 20.0% | 33.0% | 28.0% |
| Net Profit | 24 | 74 | 50 | 50 | 35 | 50 | 47 | 46 | 45 | 37 | 30 | 24 | 29 | 38 |
| Exceptional Items | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 3.0 | 9.2 | 6.2 | 6.3 | 4.3 | 6.3 | 5.8 | 5.7 | 5.5 | 4.6 | 3.7 | 3.0 | 3.5 | 4.8 |
| Sales Growth (YoY) | 31.0% | 50.5% | 10.8% | 20.5% | -9.9% | 16.5% | 32.9% | 18.6% | 22.0% | 11.3% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -31.4% | 34.5% | 3.0% | 37.9% | -21.2% | -1.1% | 12.1% | 3.1% | 1.9% | 12.9% | 0.0% | 6.1% | -7.0% | -- |
| OP Growth (YoY) | -9.6% | 44.1% | 9.1% | 12.3% | -17.5% | 21.4% | 61.0% | 103.1% | 43.2% | 1.8% | -- | -- | -- | -- |
| OP Growth (QoQ) | -52.0% | 36.1% | -1.4% | 40.4% | -23.5% | 3.0% | 1.5% | 3.2% | 12.5% | 36.6% | 28.1% | -27.3% | -20.0% | -- |
| Profit Growth (YoY) | -30.9% | 47.3% | 6.9% | 9.3% | -22.1% | 36.4% | 57.0% | 93.3% | 56.6% | -3.4% | 212.9% | 41.6% | 12.9% | -17.0% |
| EPS Growth (YoY) | -30.8% | 47.3% | 6.2% | 9.4% | -22.2% | 36.4% | 57.0% | 92.9% | 56.8% | -3.4% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -67.6% | 49.4% | -1.6% | 45.1% | -31.0% | 7.8% | 1.4% | 3.2% | 20.9% | 24.1% | 24.6% | -16.1% | -25.5% | -- |
| OP Margin | 24.7% | 35.4% | 35.0% | 36.5% | 35.9% | 37.0% | 35.5% | 39.2% | 39.1% | 35.4% | 29.3% | 22.9% | 33.3% | 38.7% |
| Net Margin | 12.6% | 26.7% | 24.3% | 25.0% | 24.1% | 27.2% | 25.3% | 27.7% | 27.9% | 23.4% | 21.4% | 17.1% | 22.0% | 26.8% |
| Material Cost % | 29.7% | 38.1% | 29.6% | 27.9% | 21.9% | 29.8% | 33.3% | 27.7% | 30.3% | 36.8% | 39.0% | 44.0% | 35.8% | 33.4% |
| Employee Cost % | 15.0% | 9.0% | 12.0% | 12.3% | 15.6% | 11.4% | 10.7% | 11.8% | 12.5% | 10.8% | 12.5% | 12.5% | 11.7% | 10.8% |
| P/S | 7.43 | 7.91 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 32.68 | 31.31 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 5.41 | 5.47 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Voting Results and Scrutinizer''s Report for the Postal ballot conducted by the Company are enclosed herewith.
Scrutinizer''s Report and Voting Results for Postal ballot conducted by the Company are enclosed herewith.
Earnings Call Transcript of the Earning Call for Unaudited Financial Results for quarter ended June 30, 2026 is enclosed.
Audio Link for outcome of Results Earnings Call for United Financial Results for quarter ended June 30, 2026 is enclosed.
Enclosed herewith Copy of Newspaper Publication of Results for quarter ended June 30, 2026.
Press Release for Unaudited Financial Results for quarter ended June 30, 2026 is enclosed herewith.
Investor Presentation for Results Earnings Call for Unaudited Financial Results for quarter ended June 30,2026 is enclosed herewith.
Unaudited Financial Results for the quarter ended June 30, 2026 is enclosed.
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held ....
Intimation of the Earnings call for Unaudited Financial Results of the Company for the quarter ended June 30, 2026 is enclosed herewith.
Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve In terms of Regulation ....
Please find attached copy of Newspaper Publication of Postal Ballot Notice.
Please Find Attached Postal Ballot Notice of Supriya Lifescience Limited.
Enclosed herewith is the Certificate under Regulation 74 (5) of SEBI (DP) Regulations, 2018, received from RTA.
Enclosed herewith is the intimation for submission under Regulation 30 of SEBI (LODR) Regulations, 2015.
Email Communication to Shareholders regarding Dividend Taxation Provisions.
Enclosed herewith is the intimation for trading window closure for declaration of Unaudited Financial Results for quarter ending on June 30, 2026.
Intimation of Analyst / Investor Meeting is enclosed herewith.
Intimation of Investor/Analyst call is enclosed.
Earnings Call Transcript is enclosed herewith.
Enclosed herewith is the Annual Secretarial Compliance Report
Audio Recording and Outcome of Earnings Call is enclosed herewith.
Newspaper Publication of Audited Financial Results is enclosed herewith.
Enclosed herewith is the Press Release.
Enclosed herewith announcement pertaining to Dividend declared by the Company at its Board Meeting
Investor Presentation enclosed herewith.
Audited Financial Results for quarter and year March 31, 2026.
Outcome of the Board Meeting is enclosed herewith.
Results Earnings Call for the Audited Financial Results for quarter and year ended march 31, 2026 is enclosed herewith along with dial in details and link for joining the call. Kindly ....
Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve In terms of Regulation ....
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Enclosed herewith Announcement pertaining to update on USFDA.
Voting Results and Scrutinizers Report for Postal Ballot conducted by the Company are enclosed herewith.
The Scrutinizers Report and Voting Results for the Postal Ballot Conducted by the Company are enclosed herewith.
Enclosed herewith is the Certificate under Regulation 74 (5) of SEBI (Depository and Participants) Regulation, 2018 for the quarter ended March 31, 2026. Kindly take the same on record
Intimation for Closure of Trading Window for declaration of Audited Financial Results for quarter and year ending March 31, 2026 is enclosed herewith. Kindly take the same on record.
Enclosed herewith are the details of Change in Management with regards to completion of tenure of Independent Directors of the Company. Kindly take the same on record.
Enclosed herewith Newspaper Extract of Postal Ballot Notice dispatched to Shareholders.
Please find attached Postal Ballot Notice of Supriya Lifescience Limited.
Transcript of the Earnings Call for the Unaudited Financial Results for quarter and nine months ended December 31, 2025, is enclosed herewith. Kindly take the same on record.
Audio Recording of the Earnings Call for Unaudited Financial Results of quarter and nine months ended December 31, 2025 is enclosed herewith.
Newspaper Publication of Unaudited Financial Results for the quarter and nine months ended December 31, 2025 is enclosed.
Press Release for Unaudited Financial Results for quarter and nine months ended December 31, 2025 is enclosed.
Investor Presentation for Results Earnings Call for Quarter and Nine Months ended on December 31, 2025 is enclosed herewith. Kindly take the same on record.
Details of Appointment and Re-appointment of independent Directors of the Company are enclosed herewith. Kindly take the same on record.
Financial Results for Quarter and Nine Months ended on December 31, 2025.
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held ....
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that an earnings call will be held on Tuesday, February 10, ....
Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 ,inter alia, to consider and approve In terms of Regulation ....
Certificate under Regulation 74 (5) of SEBI (Depositories & Participants) Regulations, 2018 for quarter ended December 31, 20205 is enclosed.
Credit Ratings
6Concalls
19Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Jan 2025
31 Jan 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024Jun 2024
30 Jun 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023Jun 2023
30 Jun 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022May 2022
31 May 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Jan 2022
31 Jan 2022Held by ETFs
3 ETFs hold SUPRIYA · sorted by weight
Held by Mutual Funds
9 schemes hold SUPRIYA · sorted by weight